The American Journal of Managed Care: AJMC Stakeholder Summit: Advancing Hepatic Encephalopathy Management
Dr. Derek van Amerongen introduces a panel discussing hepatic encephalopathy (HE), noting that 30-40% of cirrhotic patients develop overt HE. Dr. Arun Jesudian explains that hepatic encephalopathy (HE ...
"Post-TIPS HE [hepatic encephalopathy] may reflect the patients' overall vulnerability leading to an increased risk for complications and thus explaining the overall poorer prognosis of these patients ...
News Medical: High cost of hepatic encephalopathy treatment may lead to medication non-adherence
Researchers from the University of Minnesota Medical School and College of Pharmacy have found that high costs for hepatic encephalopathy treatment in patients with end-stage liver disease were ...
Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy compared with lactulose monotherapy, a ...
FiercePharma: Salix gets real patient to talk about the risk of overt hepatic encephalopathy
Bausch Health’s gastroenterology business arm, Salix, is using its new spot for Xifaxan to educate patients with cirrhosis of the liver about the risk of overt hepatic encephalopathy (OHE). Up to 80% ...
Salix gets real patient to talk about the risk of overt hepatic encephalopathy
News Medical: Evaluating biomarkers for diagnosing minimal hepatic encephalopathy in cirrhotic patients
Healio: Rifaximin reduces risk for overt hepatic encephalopathy recurrence by 60% vs. lactulose
Rifaximin reduces risk for overt hepatic encephalopathy recurrence by 60% vs. lactulose
Salix Pharmaceuticals, the gastroenterology unit of Bausch Health, is linking up with actor Bellamy Young to raise awareness about hepatic encephalopathy, a brain disease associated with advanced ...
Science Daily: Could your phone detect hepatic encephalopathy by listening to you read?